Ifm_05-may 2022 May 2026

Lenalidomide was the primary drug used for maintenance in this study. Key Findings:

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. IFM_05-May 2022

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. Lenalidomide was the primary drug used for maintenance

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022